Digital Mental Health: A Narrative Review of FDA-Authorized Products for Psychiatric Treatment and Diagnostic Support

Objective: To identify FDA-authorized prescription or clinician-directed digital mental health products, including applications and software-enabled devices, for psychiatric treatment or diagnostic support. Methods: FDA Medical Device Databases were searched for records associated with nine product codes relevant to digital mental health. Eligible records were consolidated into distinct product families. Peer-reviewed literature and FDA documentation were reviewed to characterize indications, authorization pathways, and the quality of supporting evidence. Results: Sixteen digital mental health products and software-enabled devices authorized by the FDA met the inclusion criteria. Twelve products supported treatment for substance use disorders, insomnia, attention-deficit/hyperactivity disorder (ADHD), posttraumatic stress disorder (PTSD)-related conditions, major depressive disorder, generalized anxiety disorder, and postpartum depression. Four products provided diagnostic support for ADHD or autism spectrum disorder. Authorization was granted through either 510(k) clearance or De Novo classification, with considerable variation in the quantity, independence, and clinical relevance of supporting evidence. Conclusions: FDA marketing authorization does not uniformly indicate clinical effectiveness. Because 510(k) clearance, De Novo classification, and premarket approval (PMA) reflect distinct regulatory standards, clinicians should interpret digital mental health products in the context of the specific authorization pathway, product indication, and supporting evidence base.